FluoGuide’s presentation at Økonomisk Ugebrev’s Life Science event is now available

Copenhagen, Denmark, 26 November 2020 – Yesterday, FluoGuide A/S (“FluoGuide” or the “Company”) presented at Økonomisk Ugebrev’s Life Science event. The recorded presentation is now available (in Danish only) here.

Økonomisk Ugebrev Life Science conveys the potential of Nordic equities in the BioTech and pharmaceutical sectors. The magazine is aimed at both the prudent investor with an interest in stable pharmaceutical and MedTech companies, as well as investors who are prepared to go after the very large returns in the BioTech sector (https://ugebrev.dk).

The event was moderated by Økonomisk Ugebrev Life Science’s analysts, Steen Albrechtsen, Morten Larsen and Lars Hatholt.

For further information:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com

About FluoGuide

FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is undertaking a proof-of-concept clinical trial (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma including glioblastoma.

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.